Breakthrough orders for Senzime in the UK

Report this content

Press release: Uppsala, March 31, 2020. Senzime AB (publ) today announces that the company has received orders for TetraGraph systems and associated disposable sensors from the NHS-hospitals Medway Maritime Hospital and Sherwood Forest Hospital. The initial order value amounts to about SEK 0.5 million.

Medway Maritime Hospital is an NHS-hospital in Gillingham outside London that performs around 30,000 surgeries annually and provides healthcare to almost half a million patients. The NHS Sherwood Forest Hospital provides hospital services to over 420,000 patients annually. Both hospitals are now transitioning to use TetraGraph to monitor patients undergoing anesthesia with neuromuscular blocking agents.

The orders have been secured through Senzime's new distributor in the UK - Healthcare 21 - one of Northern Europe's largest privately owned healthcare companies operating in the UK, Ireland, Germany and Austria. Healthcare 21 is a leading distributor for several market-leading global medical technology companies. Senzime signed an agreement with Healthcare 21 in February 2020.

“The interest in TetraGraph is great in the UK - a market with over 1,250 hospitals and clarified clinical guidelines with requirements and recommendations for switching to objective patient monitoring. TetraGraph meets these exact requirements and the demand for patient monitoring is strong even though healthcare is suffering from a very high burden right now”, says Pia Renaudin, CEO Senzime.

Senzime’s TetraGraph neuromuscular monitor is a unique digital system designed to address the needs of perioperative monitoring of physiologic data in surgical patients receiving general anesthesia and muscle relaxation using neuromuscular blocking drugs (NMBAs). The TetraGraph stimulates a peripheral nerve and measures, analyzes and displays in real-time the muscle function.

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                          

Tel: +46 (0)70-813 34 17, email:     


About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq
First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, is Certified Adviser for Senzime.

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on March 31, 2020, 12:00




Documents & Links